© 1995 American Heart Association, Inc.
Articles |
Effects of 1 Year of Growth Hormone Therapy on Serum Lipoprotein Levels in Growth Hormone–Deficient Adults
Influence of Gender and Apo(a) and ApoE Phenotypes
Presented in part at the First International Meeting of the Growth Hormone Research Society, Aarhus, Denmark, June 1-4, 1994.
From the Research Centre for Endocrinology and Metabolism (G.J., J.O., T.R., B.-Å.B.) and the Wallenberg Laboratory (O.W., G.O.), Sahlgrenska University Hospital, and the Department of Medicine (L.W.), Östra University Hospital, Göteborg, Sweden.
Correspondence to Gudmundur Johannsson, MD, Research Centre for Endocrinology and Metabolism, Sahlgrenska University Hospital, S-413 45 Göteborg, Sweden. E-mail gudmundur.johannsson@ ss.gu.se.
Abstract We investigated the influence of gender and apoE and apo(a) phenotypes as well as the effect of the metabolic effects of growth hormone (GH) on the effect of GH therapy on serum lipoprotein concentrations in GH-deficient (GHD) adults. Forty-four consecutive patients, 30 men and 14 women aged 46.5 (range, 19 to 76) years with GHD due mainly to pituitary tumors, were treated with recombinant human GH for 12 months. Serum concentrations of lipoproteins, insulin, thyroxine, and insulin-like growth factor–I were determined, body composition was assessed by bioelectrical impedance, and apo(a) and apoE phenotypes were analyzed. Lipoprotein(a) [Lp(a)] concentrations in the GHD subjects were compared with a gender- and apo(a) phenotype–matched control group. After 12 months of GH treatment, the total cholesterol, LDL cholesterol, and apoB concentrations decreased, the HDL cholesterol and apoE concentrations increased, and the apoA-I and triglyceride concentrations were unchanged. Before treatment, the Lp(a) concentration was similar to that in the control group. However, after 12 months of treatment, the Lp(a) concentration had increased by 44% and 101% above baseline and the control group, respectively. Men and women responded differently to GH, with a more marked increase in Lp(a) concentration and fat-free mass and a more pronounced decrease in body-fat mass in men. Apo(a) phenotypes had no major influence on the effect of GH therapy. The only significant difference between apoE phenotypes was a higher baseline Lp(a) concentration among apoE4 heterozygotes. Changes in body composition, insulin, insulin-like growth factor–I, and thyroxine concentrations explained at most 27% of the changes that occurred in serum lipoprotein levels during GH treatment. The effects of GH therapy on serum lipoprotein levels and body composition in GHD adults were dependent in part on gender or current sex hormone therapy. However, no major influence by apo(a) or apoE phenotype or changes in metabolic variables were detected on the effects of GH therapy on serum lipoprotein levels.
Key Words: growth hormone • lipoproteins • apo(a) phenotype • apoE phenotype • gender
This article has been cited by other articles:
 |
|
 |
|
  T. S. Hannon, K. Danadian, C. Suprasongsin, and S. A. Arslanian Growth Hormone Treatment in Adolescent Males with Idiopathic Short Stature: Changes in Body Composition, Protein, Fat, and Glucose Metabolism J. Clin. Endocrinol. Metab., August 1, 2007; 92(8): 3033 - 3039. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Franco, J. Brandberg, L. Lonn, B. Andersson, B.-A. Bengtsson, and G. Johannsson Growth Hormone Treatment Reduces Abdominal Visceral Fat in Postmenopausal Women with Abdominal Obesity: A 12-Month Placebo-Controlled Trial J. Clin. Endocrinol. Metab., March 1, 2005; 90(3): 1466 - 1474. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K.-C. Leung, G. Johannsson, G. M. Leong, and K. K. Y. Ho Estrogen Regulation of Growth Hormone Action Endocr. Rev., October 1, 2004; 25(5): 693 - 721. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. R. Christ, M. H. Cummings, N. Jackson, M. Stolinski, P. J. Lumb, A. S. Wierzbicki, P. H. Sonksen, D. L. Russell-Jones, and A. M. Umpleby Effects of Growth Hormone (GH) Replacement Therapy on Low-Density Lipoprotein Apolipoprotein B100 Kinetics in Adult Patients with GH Deficiency: A Stable Isotope Study J. Clin. Endocrinol. Metab., April 1, 2004; 89(4): 1801 - 1807. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
O. Serri, L. Li, F. Maingrette, N. Jaffry, and G. Renier Enhanced Lipoprotein Lipase Secretion and Foam Cell Formation by Macrophages of Patients with Growth Hormone Deficiency: Possible Contribution to Increased Risk of Atherogenesis? J. Clin. Endocrinol. Metab., February 1, 2004; 89(2): 979 - 985. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Lind, M. Rudling, S. Ericsson, H. Olivecrona, M. Eriksson, B. Borgstrom, G. Eggertsen, L. Berglund, and B. Angelin Growth Hormone Induces Low-Density Lipoprotein Clearance but not Bile Acid Synthesis in Humans Arterioscler. Thromb. Vasc. Biol., February 1, 2004; 24(2): 349 - 356. [Abstract] [Full Text]
|
|
|
|
|
|
K. Landin-Wilhelmsen, I. Bryman, and L. Wilhelmsen Cardiac Malformations and Hypertension, But Not Metabolic Risk Factors, Are Common in Turner Syndrome J. Clin. Endocrinol. Metab., September 1, 2001; 86(9): 4166 - 4170. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Sesmilo, B. M. K. Biller, J. Llevadot, D. Hayden, G. Hanson, N. Rifai, and A. Klibanski Effects of Growth Hormone (GH) Administration on Homocyst(e)ine Levels in Men with GH Deficiency: A Randomized Controlled Trial J. Clin. Endocrinol. Metab., April 1, 2001; 86(4): 1518 - 1524. [Abstract] [Full Text]
|
|
|
|
|
|
T. B. Twickler, H. W. Wilmink, P. C. N. J. Schreuder, M. C. Cabezas, P. S. van Dam, H. P. F. Koppeschaar, D. W. Erkelens, and G. M. Dallinga-Thie Growth Hormone (GH) Treatment Decreases Postprandial Remnant-Like Particle Cholesterol Concentration and Improves Endothelial Function in Adult-Onset GH Deficiency J. Clin. Endocrinol. Metab., December 1, 2000; 85(12): 4683 - 4689. [Abstract] [Full Text]
|
|
|
|
 |
|
 D. Linden, A. Sjoberg, L. Asp, L. Carlsson, and J. Oscarsson Direct effects of growth hormone on production and secretion of apolipoprotein B from rat hepatocytes Am J Physiol Endocrinol Metab, December 1, 2000; 279(6): E1335 - E1346. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Sesmilo, B. M.K. Biller, J. Llevadot, D. Hayden, G. Hanson, N. Rifai, and A. Klibanski Effects of Growth Hormone Administration on Inflammatory and Other Cardiovascular Risk Markers in Men with Growth Hormone Deficiency: A Randomized, Controlled Clinical Trial Ann Intern Med, July 18, 2000; 133(2): 111 - 122. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. A. M. Beentjes, A. van Tol, W. J. Sluiter, and R. P. F. Dullaart Effect of growth hormone replacement therapy on plasma lecithin:cholesterol acyltransferase and lipid transfer protein activities in growth hormone-deficient adults J. Lipid Res., June 1, 2000; 41(6): 925 - 932. [Abstract] [Full Text]
|
|
|
|
|
|
N. Vahl, A. Juul, J. O. L. Jørgensen, H. Ørskov, N. E. Skakkebæk, and Jens. S. Christiansen Continuation of Growth Hormone (GH) Replacement in GH-Deficient Patients during Transition from Childhood to Adulthood: A Two-Year Placebo-Controlled Study J. Clin. Endocrinol. Metab., May 1, 2000; 85(5): 1874 - 1881. [Abstract] [Full Text]
|
|
|
|
 |
|
 L. Normen, P. Dutta, A. Lia, and H. Andersson Soy sterol esters and {beta}-sitostanol ester as inhibitors of cholesterol absorption in human small bowel Am. J. Clinical Nutrition, April 1, 2000; 71(4): 908 - 913. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B.-A. Bengtsson and G. Johannsson The Treatment of Growth Hormone Deficiency in Adults J. Clin. Endocrinol. Metab., March 1, 2000; 85(3): 933 - 937. [Full Text]
|
|
|
|
|
|
B. Bülow, L. Hagmar, J. Eskilsson, and E. M. Erfurth Hypopituitary Females Have a High Incidence of Cardiovascular Morbidity and an Increased Prevalence of Cardiovascular Risk Factors J. Clin. Endocrinol. Metab., February 1, 2000; 85(2): 574 - 584. [Abstract] [Full Text]
|
|
|
|
|
|
Discontinuation of Growth Hormone (GH) Treatment: Metabolic Effects in GH-Deficient and GH-Sufficient Adolescent Patients Compared with Control Subjects J. Clin. Endocrinol. Metab., December 1, 1999; 84(12): 4516 - 4524. [Abstract] [Full Text]
|
|
|
|
|
|
B.-A. Bengtsson, R. Abs, H. Bennmarker, J. P. Monson, U. Feldt-Rasmussen, E. Hernberg-Ståhl, B. Westberg, P. Wilton, and C. Wüster The Effects of Treatment and the Individual Responsiveness to Growth Hormone (GH) Replacement Therapy in 665 GH-Deficient Adults J. Clin. Endocrinol. Metab., November 1, 1999; 84(11): 3929 - 3935. [Abstract] [Full Text]
|
|
|
|
|
|
R. Tao, F. Acquati, S. M. Marcovina, and H. H. Hobbs Human Growth Hormone Increases Apo(a) Expression in Transgenic Mice Arterioscler. Thromb. Vasc. Biol., October 1, 1999; 19(10): 2439 - 2447. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Svensson, J.-O. Jansson, M. Ottosson, G. Johannsson, M.-R. Taskinen, O. Wiklund, and B.-A. Bengtsson Treatment of Obese Subjects with the Oral Growth Hormone Secretagogue MK-677 Affects Serum Concentrations of Several Lipoproteins, But Not Lipoprotein(a) J. Clin. Endocrinol. Metab., June 1, 1999; 84(6): 2028 - 2033. [Abstract] [Full Text]
|
|
|
|
|
|
M. Leonsson, J. Oscarsson, I. Bosaeus, B. K. Lundgren, G. Johannsson, O. Wiklund, and B. A. Bengtsson Growth Hormone (GH) Therapy in GH-Deficient Adults Influences the Response to a Dietary Load of Cholesterol and Saturated Fat in Terms of Cholesterol Synthesis, But Not Serum Low Density Lipoprotein Cholesterol Levels J. Clin. Endocrinol. Metab., April 1, 1999; 84(4): 1296 - 1303. [Abstract] [Full Text]
|
|
|
|
|
|
F. Borson-Chazot, A. Serusclat, Y. Kalfallah, X. Ducottet, G. Sassolas, S. Bernard, F. Labrousse, J. Pastene, A. Sassolas, Y. Roux, et al. Decrease in Carotid Intima-Media Thickness after One Year Growth Hormone (GH) Treatment in Adults with GH Deficiency J. Clin. Endocrinol. Metab., April 1, 1999; 84(4): 1329 - 1333. [Abstract] [Full Text]
|
|
|
|
|
|
U. Querfeld, S. Döpper, A. Gradehand, P. Kiencke, F. Wahn, and H.-J. Zeisel Long-Term Treatment with Growth Hormone Has No Persisting Effect on Lipoprotein(a) in Patients with Turner's Syndrome J. Clin. Endocrinol. Metab., March 1, 1999; 84(3): 967 - 970. [Abstract] [Full Text]
|
|
|
|
|
|
P. V. Carroll, E. R. Christ the members of Growth Hormone Research Soci, B. A. Bengtsson, L. Carlsson, J. S. Christiansen, D. Clemmons, R. Hintz, K. Ho, Z. Laron, P. Sizonenko, et al. Growth Hormone Deficiency in Adulthood and the Effects of Growth Hormone Replacement: A Review J. Clin. Endocrinol. Metab., February 1, 1998; 83(2): 382 - 395. [Abstract] [Full Text]
|
|
|
|
|
|
A. von Eckardstein, S. Kliesch, E. Nieschlag, A. Chirazi, G. Assmann, and H. M. Behre Suppression of Endogenous Testosterone in Young Men Increases Serum Levels of High Density Lipoprotein Subclass Lipoprotein A-I and Lipoprotein(a) J. Clin. Endocrinol. Metab., October 1, 1997; 82(10): 3367 - 3372. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. M. Boot, M. A. M. J. Engels, G. J. M. Boerma, E. P. Krenning, and S. M. P. F. de Muinck Keizer-Schrama Changes in Bone Mineral Density, Body Composition, and Lipid Metabolism during Growth Hormone (GH) Treatment in Children with GH Deficiency J. Clin. Endocrinol. Metab., August 1, 1997; 82(8): 2423 - 2428. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Johannsson, MD, B.-A. Bengtsson, and Ph. D. Growth Hormone Therapy in GH-Deficient Adults: The Problem of the Dose--Authors' Response J. Clin. Endocrinol. Metab., April 1, 1997; 82(4): 1305 - 1306. [Full Text]
|
|